Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study | Oleichik | Psychiatry (Moscow) (Psikhiatriya)

Psychiatry (Moscow) (Psikhiatriya)
Psychiatry (Moscow)

ISSN 1683-8319 (Print)
ISSN 2618-6667 (Online)

eng | рус

Preview

Psychiatry (Moscow) (Psikhiatriya)

Advanced search

Archives

Download this PDF file

For citations:

Oleichik I.V., Baranov P.A., Shishkovskaia T.I. Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study. Psychiatry (Moscow) (Psikhiatriya). 2023;21(3):6-19. (In Russ.) https://doi.org/10.30629/2618-6667-2023-21-3-6-19

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1683-8319 (Print)
ISSN 2618-6667 (Online)

* not an advertisement

Подписка на Журнал «ПСИХИАТРИЯ»

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Julia A. Chaika

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

I. V. Oleichik
ФГБНУ «Научный центр психического здоровья»
Russian Federation

Igor V. Oleichik, Dr. of Sci. (Med.), Chief Researcher, Department of Endogenous Mental Disorders and Affective Conditions

Moscow

P. A. Baranov
ФГБНУ «Научный центр психического здоровья»
Russian Federation

Pyotr A. Baranov, Cand. of Sci. (Med.), Leading Researcher, Department of Endogenous Mental Disorders and Affective Conditions

Moscow

T. I. Shishkovskaia
ФГБНУ «Научный центр психического здоровья»
Russian Federation

Tatiana I. Shishkovskaia, Junior Researcher, Department of Endogenous Mental Disorders and Affective Conditions

Moscow

Notifications